Wells Fargo & Company Calliditas Therapeutics Ab Transaction History

Wells Fargo & Company

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$17.65 - $41.41 $39,889 - $93,586	-2,260 Reduced 60.11%	1,500 $58,000
Q1 2024 May 10, 2024	BUY	$20.04 - $25.66 $45,290 - $57,991	2,260 Added 150.67%	3,760 $78,000
Q4 2023 Feb 09, 2024	BUY	$15.79 - $28.99 $23,685 - $43,485	1,500 New	1,500 $38,000
Q2 2022 Aug 12, 2022	SELL	$12.85 - $20.36 $8,082 - $12,806	-629 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$15.14 - $25.55 $5,223 - $8,814	345 Added 121.48%	629 $12,000
Q2 2021 Aug 16, 2021	BUY	$26.02 - $31.17 $7,389 - $8,852	284 New	284 $8,000

20.3K

Ticker CALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,624,800
Market Cap $1.06B
Description
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.